Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment

Soo-Churl Cho, Bung-Nyun Kim, Tarrant Cummins, Jae-Won Kim, Mark Bellgrove

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)


The purpose of this study was to investigate a possible association between norepinephrine genes and cardiovascular side effects of the Osmotic Controlled-Release Oral Delivery System-methylphenidate (OROS-MPH) in Korean children with attention-deficit/hyperactivity disorder (ADHD). One hundred and one children with ADHD (8.7-1.7 years) were recruited from child psychiatric centers at six university hospitals in South Korea. All participants were drug-naive ADHD children treated with OROS-MPH for 12 weeks. During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects. Resting heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) were examined before and after treatment.
Original languageEnglish
Pages (from-to)380 - 389
Number of pages10
JournalJournal of Psychopharmacology
Issue number3
Publication statusPublished - 2012
Externally publishedYes

Cite this